Live
- Shinkansen services near Tokyo delayed due to maintenance problem
- India sees over 226 pc surge in startup funding at $596 mn this week
- 178 Drivers turned up on the first day for and Eye Check-up Camp hosted by the IRB Golconda Expressway
- A star beyond the screen celebrates another year of excellence
- Russell stunned with pole in Las Vegas, says 'Got to deep dive into why we’re so quick'
- BJP hijacked electoral machinery for securing victory in Maharashtra: Cong
- Guwahati to host Indian National Rally Sprint Championship on Sunday
- Priyanka will now be seen in Wayanad more often: Robert Vadra
- Cong won all 3 seats on basis of guarantees, development: Dy CM on K’taka bypolls
- Santosh Trophy: Odisha rout Chhattisgarh to make final rounds
Zydus gets USFDA nod to market generic medication
Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
New Delhi: Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Methylene Blue injection in strengths of 10mg/2ml and 50mg/5ml, the drug firm said in a statement. Zydus' product is the generic version of ProvayBlue injection.
The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation, the company stated. From a hospital perspective, a vial presentation is an affordable option with significant benefits and advantages, it added.
Methylene Blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. As per IQVIA MAT data, Methylene Blue injection (10mg/2ml and 50mg/5ml) had an annual sale of around USD 73.4 million in the US.
